KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - KALA BIO, Inc. has announced a registered direct offering of 10,000,000 shares of its common stock at a price of $1.00 per share, aiming to raise approximately $10 million in gross proceeds for debt repayment and general corporate purposes [1][2]. Group 1: Offering Details - The offering is priced at-the-market under Nasdaq rules and is expected to close on or about December 5, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. - The net proceeds from the offering will be used to repay certain indebtedness and for general corporate purposes [2]. Group 2: Company Background - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and severe eye diseases [5]. - The company's lead product candidate, KPI-012, is based on its proprietary mesenchymal stem cell secretome platform and has received Orphan Drug and Fast Track designations from the FDA for treating persistent corneal epithelial defect [5].